Advertisement
An audio Web cast of the Company's presentation will be available by goingto the investor relations section of NeurogesX's Web site atwww.neurogesx.com. A replay of the presentation will be available for 30 days.
Advertisement
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused ondeveloping novel pain management therapies. Its initial focus is on chronicperipheral neuropathic pain, including postherpetic neuralgia (PHN), painfulHIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy.NeurogesX' late stage product portfolio is led by its product candidateNGX-4010, a topical patch designed to manage pain associated with peripheralneuropathic pain conditions, that the company believes offers significantadvantages over other pain therapies. Three Phase 3 clinical trials withNGX-4010 have been completed and have met their primary endpoints, two in PHNand one in HIV-DSP.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of thePrivate Securities Litigation Reform Act of 1995 (the "Act"). NeurogesXdisclaims any intent or obligation to update these forward-looking statements,and claims the protection of the Safe Harbor for forward-looking statementscontained in the Act. Examples of such statements include, but are not limitedto, statements relating to the advantages of NGX-4010 over other paintherapies. Such statements are based on management's current expectations, butactual results may differ materially due to various risks and uncertainties,including, but not limited to, NeurogesX' product candidate may haveunexpected adverse side effects or inadequate therapeutic efficacy; positiveresults in clinical trials may not be sufficient to obtain FDA or Europeanregulatory approval; physician or patient reluctance to use NGX-4010, ifapproved, or the inability of physicians to obtain sufficient reimbursementfor such procedures; potential alternative therapies; maintaining adequatepatent or trade secret protection without violating the intellectual propertyrights of others; and other difficulties or delays in clinical development,obtaining regulatory approval, market acceptance and commercialization ofNGX-4010. For further information regarding these and other risks related toNeurogesX' business, investors should consult NeurogesX' filings with theSecurities and Exchange Commission.Date: Tuesday, September 25, 2007 Time: 9:00 a.m. EDT Place: Grand Hyatt Hotel, New York, NY
SOURCE NeurogesX
